P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
Irene M. Ghobrial,Morie A. Gertz,Betsy LaPlant,John K. Camoriano,Suzanne R. Hayman,Martha Q. Lacy,Stacey Chuma,Brianna Harris,Renee Leduc,Meghan Rourke,Stephen M. Ansell,Daniel J. DeAngelo,Angela Dispenzieri,Leif Bergsagel,Craig B. Reeder,Kenneth C. Anderson,Paul G. Richardson,Steven P. Treon,Thomas E. Witzig +18 more
TL;DR: Everolimus has high single-agent activity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and offers a potential new therapeutic strategy for this patient group.
Journal ArticleDOI
Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.
TL;DR: The pathogenesis and clinical features of Hepatic veno-occlusive disease are outlined, with an emphasis on endothelial cell injury and risk factors.
Journal ArticleDOI
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
Meletios A. Dimopoulos,Maria-Victoria Mateos,Paul G. Richardson,Rudolf Schlag,Nuriet K. Khuageva,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Antonio Palumbo,Ka Lung Wu,Dixie-Lee Esseltine,Kevin Liu,William Deraedt,Andrew Cakana,Helgi van de Velde,Jesús F. San Miguel +15 more
TL;DR: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib‐associated peripheral neuropathy in newly diagnosed patients with multiple myeloma ineligible for high‐dose therapy who received bortzomib plus melphalan–prednisone.
Journal ArticleDOI
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells
Teru Hideshima,Klaus Podar,Dharminder Chauhan,Kenji Ishitsuka,Mitsiades Constantine S,Yu-Tzu Tai,Makoto Hamasaki,Noopur Raje,Hiromasa Hideshima,George Schreiner,Aaron N. Nguyen,Tony A. Navas,Nikhil C. Munshi,Paul G. Richardson,Linda S. Higgins,Kenneth C. Anderson +15 more
TL;DR: These studies provide the framework for clinical trials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient outcome in MM.
Journal ArticleDOI
The Genome of Polaromonas sp. Strain JS666: Insights into the Evolution of a Hydrocarbon- and Xenobiotic-Degrading Bacterium, and Features of Relevance to Biotechnology
Timothy E. Mattes,Anne K. Alexander,Paul G. Richardson,A. Christine Munk,Cliff Han,Paul Stothard,Nicholas V. Coleman +6 more
TL;DR: The JS666 genome sequence provides insights into the evolution of pollutant-degrading bacteria and provides a toolbox of catabolic genes with utility for biotechnology.